Alexandre Grassin
Corporate Officer/Principal chez Calliditas Therapeutics Suisse SA
Profil
Alexandre Grassin is currently a Director at Calliditas Therapeutics Suisse SA. Previously, he worked as a Principal at Novartis AG from 2007 to 2010.
He also served as a Financial Auditor at KPMG SA. From 2010 to 2012, he was a Principal at Alexion Pharma GmbH.
Additionally, he held the position of Vice President-Finance & Administration at Calliditas Therapeutics France SAS.
Mr. Grassin's most recent former position was as the Chief Financial Officer at enGene Holdings, Inc. in 2023.
Postes actifs de Alexandre Grassin
| Sociétés | Poste | Début |
|---|---|---|
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Corporate Officer/Principal | - |
Anciens postes connus de Alexandre Grassin
| Sociétés | Poste | Fin |
|---|---|---|
| ENGENE HOLDINGS INC. | Directeur Financier/CFO | 29/11/2023 |
| Alexion Pharma GmbH | Corporate Officer/Principal | 01/01/2012 |
| NOVARTIS AG | Corporate Officer/Principal | 01/01/2010 |
| GENKYOTEX SA. | Directeur Financier/CFO | - |
KPMG SA
 KPMG SA Miscellaneous Commercial ServicesCommercial Services KPMG SA provides auditing and accounting solutions. It intervenes in the insurance, asset management, real estate, automobile, and telecommunications sectors. The firm offers risk advisory, tax and regulatory, and financial advisory services. The company was founded in 1986 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| ENGENE HOLDINGS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
KPMG SA
KPMG SA Miscellaneous Commercial ServicesCommercial Services KPMG SA provides auditing and accounting solutions. It intervenes in the insurance, asset management, real estate, automobile, and telecommunications sectors. The firm offers risk advisory, tax and regulatory, and financial advisory services. The company was founded in 1986 and is headquartered in Paris, France. | Commercial Services |
| Alexion Pharma GmbH | |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
